Skip to main content
. 2021 Feb 2;13(2):205. doi: 10.3390/pharmaceutics13020205

Table 1.

Vaccine formulations using model antigen ovalbumin (OVA) as antigen.

Group No. (n = 10) Adjuvant Adjuvant Dose µg/50 µL
1 None (OVA alone) -
2 SLA 500
3 R848 5
4 CpG 5
5 MPLA 5
6 QS-21 5
7 Pam3CSK4 5
8 Poly(I:C) 20
9 SLA + R848 500 + 5
10 SLA + CpG 500 + 5
11 SLA + MPLA 500 + 5
12 SLA + QS-21 500 + 5
13 SLA + Pam3CSK4 500 + 5
14 SLA + Poly(I:C) 500 + 20